Table 4.
Efficacy of second-line chemotherapy
| Number | RR (%) | PFS† (median) | OS‡ (median) | |
|---|---|---|---|---|
| Regimen | ||||
| Amrubicin | 25 | 4 | 1.9 m | 8.3 m |
| EP or CE | 23 | 17 | 1.9 m | 5.0 m |
| Irinotecan | 21 | 5 | 2.2 m | 5.9 m |
| S-1 | 11 | 27 | 2.4 m | 12.2 m |
| IP | 5 | 40 | 4.8 m | 8.7 m |
| Primary site | ||||
| GI | 87 | 15 | 2.3 m | 8.1 m |
| HBP | 29 | 0 | 1.6 m | 5.1 m |
| Total | 116 | 11 | 2.1 m | 6.3 m |
†
PFS from second-line chemotherapy.
‡
OS from second-line chemotherapy. CE, etoposide plus carboplatin; EP, etoposide plus cisplatin; GI, gastrointestinal tract; HBP, hepato-biliary-pancreatic system; IP, irinotecan plus cisplatin; OS, overall survival; PFS, progression-free survival; RR, response rate.